Abstract

Patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative/Ki-67-high (ER+HER2–Ki-67high) luminal breast cancer have a worse prognosis and do not respond to hormonal treatment and chemotherapy. This study sought to identify disease-related protein networks significantly associated with this subtype, by assessing in-depth proteomes of 10 lesions of high and low Ki-67 values (HOT, five; COLD, five) microdissected from the five tumors. Weighted correlation network analysis screened by over-representative analysis identified the five modules significantly associated with the HOT lesions. Pathway enrichment analysis, together with causal network analysis, revealed pathways of ribosome-associated quality controls, heat shock response by oxidative stress and hypoxia, angiogenesis, and oxidative phosphorylation. A semi-quantitative correlation of key-protein expressions, protein co-regulation analysis, and multivariate correlation analysis suggested co-regulations via network-network interaction among the four HOT-characteristic modules. Predicted highly activated master and upstream regulators were most characteristic to ER-positive breast cancer and associated with oncogenic transformation, as well as resistance to chemotherapy and endocrine therapy. Interestingly, inhibited intervention causal networks of numerous chemical inhibitors were predicted within the top 10 lists for the WM2 and WM5 modules, suggesting involvement of potential therapeutic targets in those data-driven networks. Our findings may help develop therapeutic strategies to benefit patients.

Highlights

  • Patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative/ Ki-67-high (ER+HER2–Ki-67high) luminal breast cancer have a worse prognosis and do not respond to hormonal treatment and chemotherapy

  • mass spectrometry (MS)-based proteomic analysis was performed using 10 microdissected lesions comprising five HOT and five COLD spots obtained from the five formalin-fixed paraffin-embedded (FFPE) tissue specimens of this subtype

  • Gene ontology (GO) analysis was performed on the GO Biological process, GO Molecular Function, and Protein class using the Protein Analysis THrough Evolutionary Relationships (PANTHER) version 14.1 software program

Read more

Summary

Introduction

Patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative/ Ki-67-high (ER+HER2–Ki-67high) luminal breast cancer have a worse prognosis and do not respond to hormonal treatment and chemotherapy. This study sought to identify disease-related protein networks significantly associated with this subtype, by assessing in-depth proteomes of 10 lesions of high and low Ki-67 values (HOT, five; COLD, five) microdissected from the five tumors. Luminal-B tumors comprise 15–20% of breast cancers, and are characterized by a more aggressive phenotype, higher histological grade and proliferative index, and a worse prognosis This subtype is associated with a higher recurrence rate and lower survival rates after relapse compared with the luminal-A subtype. Label-free spectral counting and identification-based semiquantitative shotgun proteomic analysis of microdissected target cancerous cells of a certain type, that characterized luminal B breast cancer tumors of ER+HER2− and Ki-67 score (> 80%), were used. This study aimed to identify disease-related protein networks associated with HOT lesions, for which the WGCNA pipeline and hypergeometric-based over-representative analysis (ORA) was applied

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call